Infectious complications in 100 consecutive heart transplant recipients

Eur J Clin Microbiol Infect Dis. 1994 Jan;13(1):12-8. doi: 10.1007/BF02026117.

Abstract

Clinical and laboratory data on infectious complications in 100 consecutive heart transplant recipients were analyzed retrospectively. The mean length of follow-up was 651 +/- 466 days. All patients received a basic immunosuppressive regimen including cyclosporine (whole blood target trough level 400-600 micrograms/l), azathioprine (1 mg/kg/day) and prednisone (0.15 mg/kg/day). Early rejection prophylaxis consisted of polyclonal rabbit antithymocyte globulin (ATG) (4 mg/kg/day for 4 days) in the first 57 patients and monoclonal murine OKT-3 (5 mg/day for 14 days) in the remaining patients. The primary cause of death was infection in three patients and rejection in 16 (p < 0.001). The incidence of infection was 0.96/patient/year (n = 179); 95 infections were nosocomial (53%), 47 community-acquired (26%) and 37 opportunistic (21%). The number of hospitalizations due to infections was fewer than that due to rejection (53 versus 246 respectively, p < 0.0001), but the mean length of hospital stay was longer in the first group (13.85 +/- 10.92 days versus 3.48 +/- 2.28 days, p < 0.001). Previous early rejection prophylaxis with OKT-3 was associated with a greater number of opportunistic and nosocomial infections compared to prophylaxis with ATG (p < 0.05), as was treatment with ATG and steroid pulses compared to steroid pulses alone in cases of opportunistic infection (p < 0.05).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antilymphocyte Serum / therapeutic use
  • Community-Acquired Infections / epidemiology*
  • Community-Acquired Infections / etiology
  • Cross Infection / epidemiology*
  • Cross Infection / etiology
  • Female
  • Follow-Up Studies
  • Graft Rejection / prevention & control
  • Heart Transplantation*
  • Humans
  • Immunocompromised Host
  • Immunosuppressive Agents / administration & dosage
  • Male
  • Middle Aged
  • Muromonab-CD3 / therapeutic use
  • Opportunistic Infections / epidemiology*
  • Opportunistic Infections / etiology
  • Postoperative Complications / epidemiology*
  • Retrospective Studies

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents
  • Muromonab-CD3